Natera, Inc. (NTRA)

NASDAQ: NTRA · IEX Real-Time Price · USD
94.47
-2.24 (-2.32%)
At close: Apr 12, 2024, 4:00 PM
94.50
+0.03 (0.03%)
After-hours: Apr 12, 2024, 6:09 PM EDT
-2.32%
Market Cap 11.26B
Revenue (ttm) 1.08B
Net Income (ttm) -434.80M
Shares Out 119.15M
EPS (ttm) -3.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 861,449
Open 96.68
Previous Close 96.71
Day's Range 93.82 - 97.16
52-Week Range 36.90 - 98.82
Beta 1.39
Analysts Strong Buy
Price Target 86.86 (-8.06%)
Earnings Date May 7, 2024

About NTRA

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplanta... [Read more]

Sector Healthcare
IPO Date Jul 2, 2015
Employees 3,293
Stock Exchange NASDAQ
Ticker Symbol NTRA
Full Company Profile

Financial Performance

In 2023, Natera's revenue was $1.08 billion, an increase of 31.99% compared to the previous year's $820.22 million. Losses were -$434.80 million, -20.63% less than in 2022.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for NTRA stock is "Strong Buy." The 12-month stock price forecast is $86.86, which is a decrease of -8.06% from the latest price.

Price Target
$86.86
(-8.06% downside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting ...

2 days ago - Business Wire

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasi...

5 days ago - Business Wire

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Associat...

8 days ago - Business Wire

Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and the Alliance for Clinical Trials in Oncology, which is part of the National Clinical Trials N...

12 days ago - Business Wire

Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a collaboration with the Fédération Francophone de Cancérologie Digestive and CHU...

26 days ago - Business Wire

New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, commented today on the 2024 Clinical Practice Guideline for the Evaluation and Management of Chro...

4 weeks ago - Business Wire

Natera to Present New Data at the 2024 SGO Annual Meeting on Women's Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residua...

4 weeks ago - Business Wire

Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received commercial insurance coverage for its Prospera Heart...

5 weeks ago - Business Wire

Natera to Participate in March Investor Conferences

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in March. Raymond ...

6 weeks ago - Business Wire

Natera Reports Fourth Quarter and Full Year 2023 Financial Results

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported its financial results for the fourth quarter and year ended December 31, 2023. Rec...

6 weeks ago - Business Wire

Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the next phase of proceedings in its patent infringement litigation against CareD...

6 weeks ago - Business Wire

Medicare Extends Coverage of Natera's Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its personalized and tumor-informed molecular residual disease (MRD) test, S...

6 weeks ago - Business Wire

Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2...

7 weeks ago - Business Wire

New Study Validates Signatera™ in Endometrial Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Gynecologic Oncology validating its personalized and tum...

2 months ago - Business Wire

New Publication Demonstrates Signatera's Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in The Journal of Thoracic and Cardiovascular Surgery demon...

2 months ago - Business Wire

Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury in the U.S. District Court for the District of Delaware has reached a...

2 months ago - Business Wire

CareDx Issues Statement in Patent Infringement Case

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...

Other symbols: CDNA
2 months ago - Business Wire

Nature Medicine Publishes Two Studies Highlighting Signatera's Clinical Utility in Patients with Gastrointestinal Malignancies

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of two new studies in Nature Medicine evaluating Natera's persona...

2 months ago - Business Wire

Natera Acquires Reproductive Health Assets from Invitae

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE: NVTA), a leading medical genetic...

2 months ago - Business Wire

Invitae Completes Sale of Reproductive Health Assets to Natera

SAN FRANCISCO , Jan. 22, 2024 /PRNewswire/ --  Invitae  (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which include...

2 months ago - PRNewsWire

Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera's Clinical Utility in CRC

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease (...

3 months ago - Business Wire

Natera Provides Update on Ravgen Trial

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury has reached a verdict in the United States District Court for the Wes...

3 months ago - Business Wire

Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced preliminary revenue results for the fourth quarter and full year ended De...

3 months ago - Business Wire

Alger's Amy Zhang gives her top small-cap stock picks for 2024

Amy Zhang, Amy Zhang Executive Vice President & Portfolio Manager at Alger, discusses the small-cap stocks she believes will outperform this year.

Other symbols: GKOS
3 months ago - CNBC Television

Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the 42nd Annual J.P. Morgan Healthcare Conference in ...

3 months ago - Business Wire